Business context and reporting period
The filing is The Estée Lauder Companies Inc.’s Form 10-K for the fiscal year ended June 30, 2021—not a standalone 2020 Q4 report. The company sells prestige skin care, makeup, fragrance and hair care in approximately 150 countries and territories through a portfolio of more than 25 brands and licensed names.
Key financial metrics
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $16.215 billion | $14.294 billion |
| Gross profit / gross margin | $12.381 billion / 76.4% | $10.742 billion / 75.2% |
| Operating income / margin | $2.618 billion / 16.1% | $606 million / 4.2% |
| Net earnings attributable to Estée Lauder | $2.870 billion | $684 million |
| Diluted EPS | $7.79 | $1.86 |
| Operating cash flow | $3.631 billion | $2.280 billion |
| Cash and cash equivalents at year-end | $4.958 billion | $5.022 billion |
| Total debt at year-end | $5.569 billion | $6.136 billion |
Reported sales increased 13% (11% in constant currency). Operating income included $228 million of restructuring and other charges. Management’s adjusted measures show operating income of $3.072 billion and diluted EPS of $6.45, excluding specified restructuring, impairment, acquisition-related and other items.
Material changes versus the prior period
- Skin care sales rose 28% to $9.484 billion, while makeup sales fell 12% to $4.203 billion. Fragrance grew 23% to $1.926 billion and hair care grew 11% to $571 million.
- Asia/Pacific sales increased 29% to $5.486 billion; Europe, the Middle East & Africa rose 11% to $6.946 billion. Americas sales were essentially flat at $3.797 billion.
- Online sales grew at a strong double-digit rate globally. Mainland China, including travel retail, represented approximately 36% of consolidated sales, versus 24% in FY2020.
- Operating results benefited substantially from lower impairment charges than in FY2020. FY2021 included $188 million of goodwill, intangible and long-lived asset impairments, compared with $1.426 billion in FY2020.
Outlook, management commentary, risks and unusual items
- COVID-19 continued to disrupt retail operations and international travel; store closures and restrictions persisted in parts of the world. Management cautioned that recovery timing, renewed outbreaks and consumer behavior remain uncertain. Makeup demand remained weak amid fewer usage occasions and mask wearing.
- The Post-COVID Business Acceleration Program is expected to produce $400–$500 million in pretax charges, with $300–$400 million of annual pretax benefits when fully implemented. The company estimates 2,000–2,500 net position reductions and closure of approximately 10%–15% of freestanding stores; completion is expected through FY2023.
- On May 18, 2021, the company increased its DECIEM ownership to approximately 76% for $1.092 billion cash. The step acquisition generated an $847 million non-cash remeasurement gain included in other income, materially lifting reported earnings. Purchase accounting remained provisional at year-end, and a put/call arrangement covers the remaining interest after three years.
- FY2021 included $84 million of government assistance, reducing cost of sales and selling, general and administrative expenses. The filing provides no clear numerical sales or EPS guidance for the next fiscal year.
- Other key risks include dependence on major retail and travel-retail customers, foreign exchange and geopolitical exposure, competitive and product-trend shifts, supply-chain and cybersecurity disruptions, and potential further impairments. One China travel-retail customer accounted for 14% of FY2021 sales.
- Liquidity: current assets were $9.768 billion and current liabilities $5.298 billion. Debt-to-total-capitalization declined to 48% from 61%; the company reported no borrowings on its $1.5 billion revolving facility at June 30, 2021. It stated that cash, operating cash flow and available credit should meet anticipated needs.
Most important facts for investors to verify
- Separate underlying performance from the $847 million DECIEM remeasurement gain and the year-over-year benefit of lower impairments; compare GAAP results with the company’s adjusted measures.
- Track whether skin care and online growth can offset continued makeup weakness and the disruption to international travel retail.
- Monitor DECIEM’s finalized purchase-price allocation, acquired intangible-asset valuations, and future put/call settlement exposure.
- Assess execution costs, store closures, workforce reductions and realized savings under the Post-COVID Business Acceleration Program.
- Review customer concentration, particularly the China travel-retail customer, and changes in receivables and working capital.